Suggestions
Kevin Hrusovsky
Biotech entrepreneur and healthcare visionary
Kevin Hrusovsky is a prominent biotech entrepreneur and healthcare visionary with an extensive career in the life sciences industry.1 He currently serves as a Board Member at da32 Life Science Tech, a position he has held since 2021.1
Career Highlights
Current Positions::
- Board Member at da32 Life Science Tech (2021 - Present)
- Chairman of the Board of Directors at 908 Devices (2013 - Present)
- Founder & Chairman of Powering Precision Health (January 2014 - Present)
Previous Leadership Roles::
- Chairman & CEO of Quanterix (March 2015 - August 2022)
- Executive Chairman of the Board at Quanterix (June 2014 - August 2022)
- President, Life Sciences & Technology at PerkinElmer (November 2011 - September 2013)
- CEO, President and Director at Caliper Life Sciences (September 2003 - October 2011)
Entrepreneurial Focus
Hrusovsky has dedicated his 30-year career to transforming medicine and healthcare.2 His work focuses on:
- Advancing precision health initiatives
- Promoting biomarker research and development
- Driving innovation in the biotech and life sciences sectors
Recognition and Achievements
Kevin Hrusovsky has received several accolades for his contributions to the industry:
- Honorary Doctorate Degree from Framingham State University (May 2000)
- Named a 2017 BBJ Innovation All-Star by the Boston Business Journal
- Finalist for Ernst & Young (EY) Entrepreneur Of The Year in 2017 and 2018
His LinkedIn profile (username: kevin-hrusovsky-219450) showcases his extensive experience and achievements in the biotech and healthcare industries.1
Highlights
Pleased to announce that Quanterix has partnered with and received funding from the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the development of a #multianalyte plasma test for the early detection of #AlzheimersDisease. Now more than ever it’s critical that we dedicate as many resources as possible to the development of highly accessible diagnostics, so that more patients have access to emerging therapies at the earliest onset of disease.
Learn more about our exciting collaboration with ADDF and Amsterdam UMC: https://bwnews.pr/3LqZlmg #EndAlz
A new Science Magazine study has revealed the key role NfL plays in #MultipleSclerosis research! Scientists leveraged Quanterix’ ability to detect the neurofilament light (NfL) protein at ultra-low levels, and as a result, discovered evidence pointing to Epstein-Barr virus (EBV) as greatly increasing the risk of subsequent #MS, and supporting its potential role in the pathogenesis of MS. We’re excited to see how this research will aid critical advances in MS discovery and development!
